In particular, immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) and its ligand PD-L1, have to date been approved by the U.S. Food and Drug Administration (FDA) for the use in the treatment of patients with 10 distinct cancer types5. This evidence concerns the gene CD274 and cancer.